Alpine Immune Sciences Inc
F:34LA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
HanmiGlobal Co Ltd
KRX:053690
|
KR |
|
D
|
Deo Ca Traffic Infrastructure Investment JSC
VN:HHV
|
VN |
|
Genus Power Infrastructures Ltd
NSE:GENUSPOWER
|
IN |
|
F
|
Fortis Inc
NYSE:FTS
|
CA |
|
Z
|
Zen Technologies Ltd
NSE:ZENTEC
|
IN |
|
B
|
BPH Global Ltd
ASX:BP8
|
AU |
Alpine Immune Sciences Inc
EPS (Diluted)
Alpine Immune Sciences Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpine Immune Sciences Inc
F:34LA
|
EPS (Diluted)
$0
|
CAGR 3-Years
26%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
Alpine Immune Sciences Inc
Glance View
Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.
See Also
What is Alpine Immune Sciences Inc's EPS (Diluted)?
EPS (Diluted)
-0.6
USD
Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's EPS (Diluted) amounts to -0.6 USD.
What is Alpine Immune Sciences Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
25%
Over the last year, the EPS (Diluted) growth was 57%. The average annual EPS (Diluted) growth rates for Alpine Immune Sciences Inc have been 26% over the past three years , 25% over the past five years .